You are here: REPAIR trial homepage | FAQ
Does the donor need to be a relative?
Who can consent patients to the REPAIR trial?
Who can carry out the intervention (Remote Ischaemic Preconditioning)?
What do I do if I have problems accessing the on line REPAIR data collection site, or have forgotten my log in details
In the protocol, it states that the intervention must be carried out for 5 minutes per cycle. How strict is this policy
Some REPAIR patients may require cytokine samples to be taken over the weekend. What should happen in these circumstances as there may not be staff available to carry this out?
If it is possible to collect some but not all samples, which are the most important ones to choose?
In the eCRF it lists a schedule of follow up appointments with populated dates. How near to this date does the follow need to be?
The renal graft information form asks for warm and cold ischaemic times, how should this be calculated?
If one of the patients is unable to tolerate the pre conditioning, what should be done?
What if the donor lives abroad? Can I still recruit a pair if the donor lives abroad and will be returning home after their operation?
At training the issue of what would happen if a patient has a working fistula in both arms has been raised on a few occasions. Should we use the leg for pre conditioning?
What happens if a pair is randomised but the transplant is cancelled at the last minute?
Can patients on anti-TNF alpha treatment be included in REPAIR?
Should patients on amiodarone be excluded from the trial?
When should the interventions be carried out?
REPAIR is an Intention to Treat (ITT) trial, what does that mean?
Can the preconditioning stimulus be applied immediately before or even during a dialysis session?
Should patients avoid fizzy drinks, coffee, tea, hot chocolate or anything containing caffeine or chocolate on the morning of or during the iohexol test?
If the patient is not weighed on the day of the Iohexol clearance can the weight recorded around the date of the 12 month follow up be used instead?
Could the function of the transplanted kidney be affected by iohexol (which is a contrast agent)?
Why does the trial use iohexol GFR as the primary endpoint, rather than a nuclear medicine GFR?
The protocol specifies CellCept mycophenolate mofetil (MMF). Is it acceptable to use generic MMF?
Some patients have contacted the REPAIR nurse at the hospital asking if they are allowed to have a decaffeinated drink prior or during the Iohexol test. Is this ok?
If a patient is randomised but for some reason (e.g. staffing issues) the interventions are not carried out but the transplant goes ahead should the patient be followed-up?
Does the PI have to sign off the CRF?
Should patients receiving Campath (alemtuzumab) induction be excluded from the study?
Are patients who are receiving intravenous immunoglobulin (IVIG) excluded from REPAIR?
Last updated 29 November 2012
